Andrea Sarah Foulkes, Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Genetic | 9 | 2011 | 3522 | 1.230 |
Why?
|
| Models, Statistical | 11 | 2019 | 5091 | 1.160 |
Why?
|
| Likelihood Functions | 4 | 2018 | 1004 | 0.870 |
Why?
|
| Metabolic Diseases | 2 | 2020 | 649 | 0.850 |
Why?
|
| Multifactorial Inheritance | 4 | 2022 | 1155 | 0.840 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 11956 | 0.830 |
Why?
|
| Software Validation | 1 | 2021 | 61 | 0.830 |
Why?
|
| Synteny | 1 | 2020 | 86 | 0.810 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 612 | 0.740 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2020 | 15606 | 0.720 |
Why?
|
| HIV-1 | 22 | 2015 | 6900 | 0.630 |
Why?
|
| Genetic Loci | 3 | 2016 | 2613 | 0.590 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 9494 | 0.590 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 4562 | 0.550 |
Why?
|
| HIV Infections | 30 | 2019 | 15906 | 0.490 |
Why?
|
| Haplotypes | 5 | 2008 | 2883 | 0.480 |
Why?
|
| Anti-HIV Agents | 15 | 2015 | 4133 | 0.470 |
Why?
|
| Genotype | 14 | 2011 | 12929 | 0.460 |
Why?
|
| Bayes Theorem | 4 | 2020 | 2064 | 0.450 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2012 | 1906 | 0.430 |
Why?
|
| Photoplethysmography | 2 | 2022 | 55 | 0.430 |
Why?
|
| Algorithms | 7 | 2021 | 13761 | 0.420 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 14439 | 0.410 |
Why?
|
| Blood Sedimentation | 2 | 2022 | 233 | 0.400 |
Why?
|
| Brain Injuries | 4 | 2022 | 1907 | 0.380 |
Why?
|
| Dyslipidemias | 6 | 2022 | 848 | 0.380 |
Why?
|
| Obesity | 6 | 2022 | 12268 | 0.370 |
Why?
|
| Biostatistics | 1 | 2011 | 160 | 0.360 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2022 | 443 | 0.350 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2022 | 594 | 0.350 |
Why?
|
| Indinavir | 3 | 2003 | 76 | 0.330 |
Why?
|
| Research Design | 2 | 2021 | 5914 | 0.330 |
Why?
|
| Lipase | 5 | 2008 | 309 | 0.320 |
Why?
|
| Genomics | 3 | 2020 | 5338 | 0.300 |
Why?
|
| Observation | 1 | 2008 | 316 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2019 | 4388 | 0.290 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2720 | 0.290 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 13635 | 0.280 |
Why?
|
| Disease | 1 | 2011 | 704 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 3 | 2007 | 2748 | 0.270 |
Why?
|
| Computational Biology | 2 | 2015 | 3564 | 0.260 |
Why?
|
| Cervix Uteri | 3 | 2019 | 578 | 0.260 |
Why?
|
| Virus Integration | 4 | 2015 | 300 | 0.260 |
Why?
|
| Humans | 79 | 2022 | 715594 | 0.260 |
Why?
|
| Apolipoprotein C-III | 1 | 2006 | 227 | 0.260 |
Why?
|
| Interferon-alpha | 3 | 2013 | 897 | 0.250 |
Why?
|
| HIV Protease Inhibitors | 3 | 2006 | 436 | 0.250 |
Why?
|
| Regression Analysis | 2 | 2011 | 6498 | 0.250 |
Why?
|
| Mucous Membrane | 2 | 2019 | 664 | 0.250 |
Why?
|
| Macrophage Activation | 2 | 2017 | 583 | 0.240 |
Why?
|
| Endotoxemia | 2 | 2017 | 218 | 0.240 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 2368 | 0.230 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2019 | 570 | 0.220 |
Why?
|
| Computer Simulation | 6 | 2017 | 6121 | 0.220 |
Why?
|
| Myocardium | 1 | 2016 | 4904 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2014 | 2582 | 0.220 |
Why?
|
| Gene Dosage | 1 | 2007 | 1268 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 1984 | 0.220 |
Why?
|
| Vagina | 2 | 2019 | 778 | 0.220 |
Why?
|
| Lipids | 2 | 2013 | 3247 | 0.220 |
Why?
|
| Consciousness Disorders | 2 | 2021 | 234 | 0.220 |
Why?
|
| Simian immunodeficiency virus | 2 | 2019 | 856 | 0.210 |
Why?
|
| Coma, Post-Head Injury | 1 | 2020 | 20 | 0.200 |
Why?
|
| Virus Replication | 5 | 2015 | 2565 | 0.200 |
Why?
|
| Databases, Genetic | 2 | 2020 | 1800 | 0.200 |
Why?
|
| Triglycerides | 2 | 2006 | 2579 | 0.200 |
Why?
|
| Viral Load | 8 | 2015 | 3281 | 0.190 |
Why?
|
| Heredity | 1 | 2020 | 164 | 0.190 |
Why?
|
| Semen | 2 | 2019 | 285 | 0.190 |
Why?
|
| Phenotype | 8 | 2019 | 16302 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 17399 | 0.180 |
Why?
|
| Leukocyte Count | 2 | 2022 | 1662 | 0.180 |
Why?
|
| Inflammation | 4 | 2021 | 10090 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3725 | 0.180 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 219 | 0.180 |
Why?
|
| Ferritins | 1 | 2022 | 582 | 0.180 |
Why?
|
| Blast Injuries | 1 | 2022 | 274 | 0.180 |
Why?
|
| Hospital Mortality | 3 | 2022 | 5140 | 0.180 |
Why?
|
| Sampling Studies | 1 | 2020 | 639 | 0.170 |
Why?
|
| Electrocardiography | 2 | 2022 | 6387 | 0.170 |
Why?
|
| Selection Bias | 1 | 2020 | 366 | 0.170 |
Why?
|
| Middle Aged | 29 | 2022 | 214639 | 0.160 |
Why?
|
| Female | 42 | 2022 | 377052 | 0.150 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 1178 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 1745 | 0.150 |
Why?
|
| Hospitals, General | 1 | 2020 | 714 | 0.150 |
Why?
|
| Confidentiality | 1 | 2021 | 603 | 0.150 |
Why?
|
| Niacin | 1 | 2017 | 115 | 0.150 |
Why?
|
| Causality | 1 | 2022 | 1180 | 0.150 |
Why?
|
| Male | 34 | 2022 | 350143 | 0.150 |
Why?
|
| Adult | 31 | 2022 | 212237 | 0.140 |
Why?
|
| Aged | 20 | 2022 | 162392 | 0.140 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 52 | 0.140 |
Why?
|
| Dendritic Cells | 4 | 2015 | 2708 | 0.140 |
Why?
|
| Prospective Studies | 10 | 2022 | 51354 | 0.130 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 2066 | 0.130 |
Why?
|
| Glutathione Transferase | 2 | 2007 | 614 | 0.130 |
Why?
|
| Probability | 1 | 2020 | 2493 | 0.130 |
Why?
|
| Macrophages | 3 | 2022 | 5746 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 427 | 0.130 |
Why?
|
| Disease Susceptibility | 3 | 2016 | 1779 | 0.120 |
Why?
|
| Biometry | 1 | 2017 | 549 | 0.120 |
Why?
|
| Linear Models | 3 | 2017 | 5983 | 0.120 |
Why?
|
| Military Personnel | 1 | 2022 | 1061 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2017 | 833 | 0.120 |
Why?
|
| Myocardial Infarction | 4 | 2016 | 11407 | 0.120 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3444 | 0.120 |
Why?
|
| Language | 1 | 2021 | 1260 | 0.120 |
Why?
|
| Lipopolysaccharides | 3 | 2022 | 2246 | 0.110 |
Why?
|
| DNA, Viral | 2 | 2012 | 2290 | 0.110 |
Why?
|
| Pedigree | 1 | 2020 | 4704 | 0.110 |
Why?
|
| Viremia | 5 | 2012 | 726 | 0.110 |
Why?
|
| Interferons | 1 | 2015 | 677 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3169 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2022 | 1359 | 0.110 |
Why?
|
| Body Composition | 1 | 2021 | 2400 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2011 | 79 | 0.110 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 23385 | 0.100 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 68 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 469 | 0.100 |
Why?
|
| Endometrium | 1 | 2014 | 407 | 0.100 |
Why?
|
| Brain Concussion | 1 | 2022 | 1284 | 0.100 |
Why?
|
| Cholesterol, HDL | 2 | 2008 | 1835 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2015 | 1183 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1124 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2008 | 3719 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1372 | 0.100 |
Why?
|
| Antiviral Agents | 2 | 2013 | 2807 | 0.100 |
Why?
|
| African Americans | 2 | 2020 | 4991 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2012 | 350 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 597 | 0.090 |
Why?
|
| Inpatients | 1 | 2020 | 2254 | 0.090 |
Why?
|
| Cluster Analysis | 4 | 2009 | 2767 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4887 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 3 | 2009 | 1636 | 0.090 |
Why?
|
| Statistical Distributions | 1 | 2008 | 65 | 0.080 |
Why?
|
| Ketamine | 1 | 2013 | 445 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 15900 | 0.080 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2008 | 115 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 189 | 0.080 |
Why?
|
| RNA | 1 | 2017 | 2607 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 580 | 0.080 |
Why?
|
| Autoantigens | 1 | 2012 | 902 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2012 | 1159 | 0.080 |
Why?
|
| Brucella abortus | 1 | 2006 | 13 | 0.080 |
Why?
|
| Cohort Studies | 10 | 2022 | 40040 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 258 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2022 | 3159 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 784 | 0.080 |
Why?
|
| Brucellosis | 1 | 2006 | 20 | 0.080 |
Why?
|
| Benzoxazines | 1 | 2008 | 302 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 11098 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3001 | 0.080 |
Why?
|
| Thyrotoxicosis | 1 | 2007 | 80 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 58293 | 0.080 |
Why?
|
| Killer Cells, Natural | 3 | 2011 | 2168 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3148 | 0.080 |
Why?
|
| Risk Factors | 8 | 2022 | 70931 | 0.080 |
Why?
|
| Sex Factors | 1 | 2021 | 10660 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2007 | 2937 | 0.070 |
Why?
|
| Consciousness | 2 | 2020 | 392 | 0.070 |
Why?
|
| South Africa | 4 | 2011 | 1610 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2022 | 62039 | 0.070 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 1589 | 0.070 |
Why?
|
| Health Resources | 1 | 2012 | 929 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 4264 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 1991 | 0.070 |
Why?
|
| Plasmodium | 1 | 2007 | 232 | 0.070 |
Why?
|
| Apolipoprotein A-I | 1 | 2006 | 292 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 968 | 0.070 |
Why?
|
| Apolipoproteins | 1 | 2007 | 311 | 0.070 |
Why?
|
| Telemedicine | 1 | 2021 | 2608 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2021 | 2920 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2006 | 598 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4276 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2003 | 76 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 2189 | 0.060 |
Why?
|
| Aging | 1 | 2022 | 8352 | 0.060 |
Why?
|
| Receptors, CCR5 | 2 | 2019 | 498 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1835 | 0.060 |
Why?
|
| Genome, Human | 1 | 2016 | 4466 | 0.060 |
Why?
|
| HIV | 2 | 2011 | 1542 | 0.060 |
Why?
|
| Leptin | 1 | 2010 | 1574 | 0.060 |
Why?
|
| Stavudine | 2 | 2012 | 90 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 199 | 0.050 |
Why?
|
| Lymphocyte Activation | 5 | 2015 | 5859 | 0.050 |
Why?
|
| Asthma | 1 | 2020 | 5946 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 23482 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2013 | 2978 | 0.050 |
Why?
|
| Hospitalization | 4 | 2022 | 9744 | 0.050 |
Why?
|
| Adiposity | 1 | 2011 | 1763 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 700 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 18583 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 459 | 0.050 |
Why?
|
| Software | 1 | 2015 | 4392 | 0.050 |
Why?
|
| Saquinavir | 1 | 2000 | 30 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 1811 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 56140 | 0.050 |
Why?
|
| Spleen | 1 | 2006 | 2458 | 0.050 |
Why?
|
| Macaca mulatta | 2 | 2019 | 2431 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 139 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 14154 | 0.050 |
Why?
|
| Ritonavir | 2 | 2012 | 311 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 13219 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 133 | 0.050 |
Why?
|
| Headache | 1 | 2007 | 1152 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2011 | 1809 | 0.050 |
Why?
|
| Monocytes | 1 | 2009 | 2627 | 0.040 |
Why?
|
| Coma | 1 | 2022 | 379 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10285 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 12285 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2022 | 8079 | 0.040 |
Why?
|
| Malaria | 1 | 2007 | 1088 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2016 | 11644 | 0.040 |
Why?
|
| Multigene Family | 1 | 2002 | 1119 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8742 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2020 | 9977 | 0.040 |
Why?
|
| Boston | 2 | 2020 | 9374 | 0.040 |
Why?
|
| United States | 2 | 2022 | 67895 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2006 | 2871 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5444 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 798 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 5034 | 0.040 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 24 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2017 | 19892 | 0.040 |
Why?
|
| Pakistan | 1 | 2016 | 291 | 0.030 |
Why?
|
| Perforin | 1 | 2015 | 171 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 524 | 0.030 |
Why?
|
| Arousal | 1 | 2020 | 1140 | 0.030 |
Why?
|
| Axons | 1 | 2022 | 1728 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4355 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2686 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 4035 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2020 | 11948 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 473 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 95 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2022 | 4263 | 0.030 |
Why?
|
| Prognosis | 4 | 2019 | 28991 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 5269 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2015 | 3248 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1144 | 0.030 |
Why?
|
| Logistic Models | 2 | 2020 | 13605 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 140 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2022 | 2191 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2015 | 503 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 643 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 1597 | 0.030 |
Why?
|
| Midazolam | 1 | 2013 | 260 | 0.030 |
Why?
|
| Cytokines | 2 | 2019 | 7190 | 0.030 |
Why?
|
| Time Factors | 5 | 2015 | 40889 | 0.030 |
Why?
|
| Apoptosis | 2 | 2022 | 9960 | 0.020 |
Why?
|
| Plasma | 1 | 2014 | 572 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2011 | 6092 | 0.020 |
Why?
|
| Lamivudine | 1 | 2011 | 339 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 216 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2021 | 72448 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 15185 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 713 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2465 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 20066 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3409 | 0.020 |
Why?
|
| Zidovudine | 1 | 2011 | 623 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2021 | 3229 | 0.020 |
Why?
|
| Adipocytes | 1 | 2016 | 1173 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 243 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2013 | 678 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 2967 | 0.020 |
Why?
|
| Carbimazole | 1 | 2007 | 4 | 0.020 |
Why?
|
| Alkynes | 1 | 2008 | 321 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2015 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 12490 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 6081 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 34429 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 27 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1699 | 0.020 |
Why?
|
| Antithyroid Agents | 1 | 2007 | 74 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2009 | 521 | 0.020 |
Why?
|
| Mutation | 4 | 2007 | 29253 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2008 | 426 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2022 | 5803 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2975 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2007 | 140 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 794 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 610 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2015 | 2315 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 641 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2015 | 1918 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1487 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2021 | 6536 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10429 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2007 | 7015 | 0.020 |
Why?
|
| Graves Disease | 1 | 2007 | 250 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 6284 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2005 | 112 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1711 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 934 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8042 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3670 | 0.020 |
Why?
|
| Brain | 2 | 2021 | 25189 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 7095 | 0.020 |
Why?
|
| Smoking | 1 | 2021 | 8950 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2007 | 600 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 1443 | 0.020 |
Why?
|
| Mortality | 1 | 2015 | 2837 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 12547 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 6274 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6727 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 19529 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6803 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 7306 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2200 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 991 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 11736 | 0.010 |
Why?
|
| Animals | 4 | 2019 | 169173 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 1681 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2005 | 885 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18175 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2005 | 914 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12495 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 1307 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23705 | 0.010 |
Why?
|
| Mothers | 1 | 2009 | 2021 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 2937 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 2792 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1893 | 0.010 |
Why?
|
| Glucose | 1 | 2010 | 4274 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 39334 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20337 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6631 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 4449 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 885 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2012 | 4088 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 7983 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4285 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6500 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9810 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 13171 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10513 | 0.010 |
Why?
|
| Child | 2 | 2009 | 74413 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 9028 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 34561 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 8897 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22636 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11238 | 0.000 |
Why?
|
| Adolescent | 1 | 2009 | 85064 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 80270 | 0.000 |
Why?
|